Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for targeting this antigen  Actimab-M remains the only CD33 targeting drug candidate for patients with multiple myeloma NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) (“Actinium” or “the Company”) announced results from an analysis performed on a large U.S. library of samples from 865 multiple myeloma patients which showed that twenty-five percent of patients had CD33 expression on their multiple myeloma cells. Actinium is currently conducting a […]